The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
I truly love this stock...in Real Life I was lucky enough to time it right and double up after the market lashed out fiercely on just about anything trading in the sector this past summer. They have a decent pipeline from what I can tell and decent prospects of selling this new drug for "eye diseases..."
At this point, unless EYLEA also creates iPad 3's out of thin air they are going to have a tough time maintaining the mojo in the short-term. For this quarter, the eight ball says 'don't count on it"...
I don't know what I am talking about perhaps but I think I am going to nail this red-thumb timing.